Robert A Williams, M.D. Radiology - Diagnostic Radiology Medicare: Accepting Medicare Assignments Practice Location: 350 Ne 12th St, Guymon, OK 73942 Phone: 580-461-1606 Fax: 580-225-5423 |
News Archive
Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML.
"The Alzheimer's Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon)," said William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer. "People with Alzheimer's, their families and caregivers desperately need more and better treatment options for this devastating, fatal brain disease."
A new drug could offer significant advantages over existing treatments for Type 2 diabetes patients who don't respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke, according to an Article published Online First in The Lancet.
Celgene Cellular Therapeutics, a wholly owned subsidiary of Celgene Corporation, today announced initial results from a Phase I multicenter safety study of PDA-001 in treatment-resistant Crohn's Disease. PDA-001 is an immunomodulatory therapy consisting of human placenta-derived cells obtained from CCT's proprietary processes.
USA Today reports on the ripple effect of this week's retirement announcements by Sen. Chris Dodd, D-Conn., and Sen. Byron Dorgan, D-N.D.: The "[t]wo Senate retirements have focused Democrats like a laser on their growing November election challenges, but a more pressing contest is less than two weeks away in an unlikely place: Massachusetts." Democrats are favored to retain the seat of the late Sen. Edward M. Kennedy, but Republicans "have increasingly touted the Jan. 19 special election as an opportunity for an upset."
› Verified 3 days ago